Neuroleptic Malignant Syndrome: A Pilot Study on Psychiatric Inpatients in Iran

Author(s): Saeed S. Shafti*, Alireza Memarie, Masomeh Rezaie, Masomeh Hamidi.

Journal Name: Current Psychopharmacology

Volume 8 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Neuroleptic malignant syndrome is a life-threatening complication that can occur anytime during antipsychotic treatment.

Objective: The present assessment has probed the incidence and clinical profile of neuroleptic malignant syndrome among a sample of non-western psychiatric patients and compared with the available data in the literature with regard to prevalence and other associated clinical physiognomies.

Methods: As a retrospective, record-based evaluation, all cases with diagnosis of neuroleptic malignant syndrome during the last sixty-two months, after ruling out other imaginable differential diagnoses, like encephalitis, meningitis and serotonin syndrome, entered the present investigation. Clinical diagnosis, was in essence also based on the Diagnostic and Statistical Manual of Mental Disorders, 5th edition. The assessment of independent variables was analyzed by ‘Compression of proportions’. Statistical significance is, defined as p value ≤0.05.

Results: Among 19814 psychiatric patients, during a sixty-two months’ period, eighteen cases received the diagnosis of neuroleptic malignant syndrome. The most prevalent symptom was fever, which was observed in 100% of cases. Also, there was no significant difference between the first generation versus second-generation antipsychotics. Neuroleptic malignant syndrome was meaningfully more prevalent among male patients suffering from schizophrenia. Similarly, it was significantly more widespread amid 18-65 years old agegroup.

Conclusion: While no significant difference was found between first-generation as opposed to second-generation antipsychotics, neuroleptic malignant syndrome was significantly more prevalent among young and male patients suffering from schizophrenia.

Keywords: Atypical antipsychotic, neuroleptic malignant syndrome, schizophrenia, typical antipsychotic, second-generation antipsychotics, clinical physiognomies.

[1]
Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist 2011; 1(1): 41-7.
[http://dx.doi.org/10.1177/1941875210386491] [PMID: 23983836]
[2]
Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocrit Care 2016; 24(1): 97-103.
[http://dx.doi.org/10.1007/s12028-015-0162-5] [PMID: 26223336]
[3]
Rajamani B, Kumar Y, Rahman SM. Neuroleptic malignant syndrome. J Family Med Prim Care 2016; 5(1): 178-80.
[http://dx.doi.org/10.4103/2249-4863.184660] [PMID: 27453870]
[4]
Tse L, Barr AM, Scarapicchia V, Vila-Rodriguez F. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol 2015; 13(3): 395-406.
[http://dx.doi.org/10.2174/1570159X13999150424113345] [PMID: 26411967]
[5]
Atsariyasing W, Goldman M. Management of medication-related adverse effects. In: Janicak PG, Tandon R, Marder S, Goldman M, Eds. Schizophrenia: recent advances in diagnosis and treatment. New York: Springer 2014; pp. 225-62.
[http://dx.doi.org/10.1007/978-1-4939-0656-7_12]
[6]
Khouri C, Planès S, Logerot S, Villier C, Mallaret M. Case report: neuroleptic malignant syndrome and diagnostic difficulties. Encephale 2016; 42(3): 277-80.
[http://dx.doi.org/10.1016/j.encep.2016.01.001] [PMID: 26923996]
[7]
Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 2004; 161(1): 160-3.
[http://dx.doi.org/10.1176/appi.ajp.161.1.160] [PMID: 14702266]
[8]
Zarrouf FA, Bhanot V. Neuroleptic malignant syndrome: Don’t let your guard down yet. Curr Psychiatr 2007; 6(8): 89.
[9]
American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association 2013; pp. 123-32.
[10]
Velamoor R. Neuroleptic malignant syndrome: A neuro-psychiatric emergency: recognition, prevention, and management. Asian J Psychiatr 2017; 29: 106-9.
[http://dx.doi.org/10.1016/j.ajp.2017.05.004] [PMID: 29061403]
[11]
Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65(4): 464-70.
[http://dx.doi.org/10.4088/JCP.v65n0403] [PMID: 15119907]
[12]
Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009; 23(6): 477-92.
[http://dx.doi.org/10.2165/00023210-200923060-00003] [PMID: 19480467]
[13]
Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 2008; 69(7): 1157-65.
[http://dx.doi.org/10.4088/JCP.v69n0716] [PMID: 18572981]
[14]
Teo DCL, Wong HK, Tan SN. Atypical Neuroleptic malignant syndrome precipitated by clozapine and quetiapine overdose: a diagnostic challenge. Innov Clin Neurosci 2018; 15(7-8): 20-2.
[PMID: 30254795]
[15]
Picard LS, Lindsay S, Strawn JR, Kaneria RM, Patel NC, Keck PE. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy 2008; 28(4): 530-5.
[http://dx.doi.org/10.1592/phco.28.4.530] [PMID: 18363536]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 8
ISSUE: 3
Year: 2019
Page: [207 - 212]
Pages: 6
DOI: 10.2174/2211556008666191004121352

Article Metrics

PDF: 11
HTML: 4
EPUB: 1
PRC: 1